TAE684 (NVP-TAE684)

Catalog No.S1108

TAE684 (NVP-TAE684) Chemical Structure

Molecular Weight(MW): 614.2

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.

Size Price Stock Quantity  
USD 160 In stock
USD 290 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) H3122 xenografts harboring the EML4-ALK translocation were treated with control vehicle or the ALK inhibitor, TAE-684, for 2 days; the tumors were excised and lysates were prepared. The TIMM results for the control and treated animals are shown. (B) H3122 cells were treated in the presence or absence of TAE-684 (100 nM) for 6 hours in the presence or absence of the indicated ligands [EGF (50 ng/mL), IGF1 (50 ng/mL), and HGF (50 ng/mL)]. Extracts were probed with the indicated antibodies.

    Cancer Res 2011 71, 4920-31. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (B) Dosage effects of TAE684 on phospho-Y1604 ALK expression of wild-type, H694R, and E1384K transfectants by Western blot analysis (top panel). Quantitative results of phospho-Y1604 ALK intensity are also (bottom panel).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

  • Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (C) Suppressive effects of TAE684 on H694R- and E1384K-induced tumors in vivo. Photographs and tumor growth curves are shown in the top and bottom panels, respectively (four mice per group).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (A) Dosage effects of TAE684 on H694R- and E1384K-induced cell proliferation measured with WST-1 activity. 

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

Purity & Quality Control

Choose Selective ALK Inhibitors

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
Targets
ALK [1]
(Cell-free assay)
3 nM
In vitro

TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M1;IS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMECwNFYxOyEQvF2= MVvTRW5ITVJ?
SF539 NUC4WVlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHYTWM2OD1yLkCwNFU3PCEQvF2= MULTRW5ITVJ?
DEL NIDWWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMECwPVI4KM7:TR?= M3\JfHNCVkeHUh?=
NB1 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HiPGlEPTB;MD6wNFE3OiEQvF2= MlHpV2FPT0WU
SR NEPjcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPxSG9KSzVyPUCuNFAzPzdizszN MmjxV2FPT0WU
KARPAS-299 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnoUm9{UUN3ME2wMlAzOzh2IN88US=> M1\kSHNCVkeHUh?=
MHH-CALL-2 NFrsNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjOXY55UUN3ME2wMlAzQTV{IN88US=> Mm\wV2FPT0WU
SU-DHL-1 Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\RfpZKSzVyPUCuNFQ5PjVizszN M37U[nNCVkeHUh?=
A4-Fuk NYW2bHFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP3TWM2OD1yLkC1OVY2KM7:TR?= MVzTRW5ITVJ?
EW-1 NFvmdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXSbIx7UUN3ME2wMlExOjV4IN88US=> M2TQeHNCVkeHUh?=
NOS-1 NX;pO|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K1[mlEPTB;MD6xNFI6PCEQvF2= MlPEV2FPT0WU
EW-16 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ZdWlEPTB;MD6xNFU3QCEQvF2= MWPTRW5ITVJ?
TE-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMU[wPVYh|ryP M2TJWnNCVkeHUh?=
SW982 NFXEWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMU[0O|gh|ryP NVzOTXZHW0GQR1XS
LAN-6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFztclZKSzVyPUCuNVc1PDNizszN MYrTRW5ITVJ?
MZ1-PC M4HMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XWVGlEPTB;MD6xO|g{PSEQvF2= MWnTRW5ITVJ?
KS-1 NHHyOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUmzOFMh|ryP MnrzV2FPT0WU
PSN1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj4TWM2OD1yLkG5OlMyKM7:TR?= NHX0XW9USU6JRWK=
LC-2-ad MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O1W2lEPTB;MD6xPVY6OiEQvF2= MWrTRW5ITVJ?
COLO-320-HSR M1jvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfkcnVKSzVyPUCuNVk4PzZizszN MYDTRW5ITVJ?
OPM-2 NFPDOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX1cGlRUUN3ME2wMlIzPjZ7IN88US=> NHrnTJZUSU6JRWK=
SK-NEP-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfqNoRXUUN3ME2wMlI{PTJ2IN88US=> M{\1SXNCVkeHUh?=
ALL-PO M1fKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrCXo1KSzVyPUCuNlQ2OjRizszN NV[xSY5{W0GQR1XS
CMK MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfTXnJEUUN3ME2wMlI2PTNizszN MVzTRW5ITVJ?
NCI-H1648 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjL[3ZHUUN3ME2wMlI4QDV3IN88US=> M1TjZXNCVkeHUh?=
SIG-M5 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMkmxOVkh|ryP NEG2eZpUSU6JRWK=
TGBC24TKB NVHyb2ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DRW2lEPTB;MD6zNFIyQCEQvF2= Mk\uV2FPT0WU
DOHH-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPWUmkyUUN3ME2wMlMyOjB2IN88US=> NXqxO5BDW0GQR1XS
NB69 M2DiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTp[4hKSzVyPUCuN|E4QDdizszN MV3TRW5ITVJ?
MFH-ino NH3NeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD4c3NUUUN3ME2wMlMzPTJ|IN88US=> MYjTRW5ITVJ?
KP-N-RT-BM-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrsOXBKSzVyPUCuN|MyOjNizszN NIHrVG5USU6JRWK=
MONO-MAC-6 M2LKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwM{OyPVEh|ryP NIX1Z4ZUSU6JRWK=
ATN-1 NV60XnBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDEcGhjUUN3ME2wMlM{OzB|IN88US=> MVrTRW5ITVJ?
NTERA-S-cl-D1 M13wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\lTWM2OD1yLkOzN|k3KM7:TR?= MnjXV2FPT0WU
L-540 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLLXZNKSzVyPUCuN|Y6QDhizszN M4HVZnNCVkeHUh?=
GB-1 M{jIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vLUmlEPTB;MD6zPFg3PyEQvF2= NF3zTplUSU6JRWK=
MV-4-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwM{m0OFYh|ryP M3jKenNCVkeHUh?=
KG-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3jTWM2OD1yLkO5OVYyKM7:TR?= NF;mSmVUSU6JRWK=
OVCAR-4 M3nE[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwNEC1Olkh|ryP Mk\nV2FPT0WU
NEC8 M1;Ucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwNEGyPVIh|ryP NVuwVWd3W0GQR1XS
SK-MM-2 NHrNVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwNEG2NFkh|ryP NFTXPHJUSU6JRWK=
TE-8 NVH5e|EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HqUWlEPTB;MD60Nlg5KM7:TR?= MXfTRW5ITVJ?
697 M2jxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DZVWlEPTB;MD60N|IyPSEQvF2= NXvhOmhSW0GQR1XS
NB14 NEW2RZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTjXYdKSzVyPUCuOFM5OjZizszN MlvLV2FPT0WU
GDM-1 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XmZWlEPTB;MD60O|EyPiEQvF2= MlLHV2FPT0WU
HUTU-80 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz3TWM2OD1yLkS3N|c2KM7:TR?= NX3MNGtMW0GQR1XS
HL-60 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTNTldZUUN3ME2wMlQ5OTR{IN88US=> MmTHV2FPT0WU
OCI-AML2 M3\lUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zHTWlEPTB;MD60PFMzQCEQvF2= MYLTRW5ITVJ?
ML-2 M{TGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwNEmwN|Eh|ryP MXzTRW5ITVJ?
ES4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDSTWM2OD1yLkS5NVA6KM7:TR?= NVz4XlR[W0GQR1XS
NCI-H747 NWPH[5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXMNWRKSzVyPUCuOFk5QSEQvF2= MU\TRW5ITVJ?
RL95-2 NVL4RWc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LURmlEPTB;MD61NFEyOiEQvF2= NYfremdSW0GQR1XS
TE-15 M1fNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjaSGU2UUN3ME2wMlUyOTJ2IN88US=> NYXZVHZzW0GQR1XS
TE-12 MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjVfZRKSzVyPUCuOVM{PDlizszN Ml[wV2FPT0WU
LB1047-RCC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LaNWlEPTB;MD61OFU1QSEQvF2= M1\6b3NCVkeHUh?=
LB831-BLC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzmUo1SUUN3ME2wMlU2ODJ|IN88US=> NWjBcpZ1W0GQR1XS
NCI-H1355 M2LacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLKO2szUUN3ME2wMlU2OTh2IN88US=> NWfyUWI1W0GQR1XS
CTV-1 M4fTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXRbZdKSzVyPUCuOVU3OjRizszN MnXwV2FPT0WU
RXF393 NFXlXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPLc4NKSzVyPUCuOVU4QTRizszN M3\hdnNCVkeHUh?=
SW872 NX;wVngyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfoZWhiUUN3ME2wMlU3PzJ2IN88US=> NWXaUWVbW0GQR1XS
MPP-89 M3fIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInhVphKSzVyPUCuOVc5QDRizszN MlLIV2FPT0WU
RPMI-8226 NXfnNpBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwNkO1NlYh|ryP Mn7CV2FPT0WU
LS-1034 NHfKcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn1b3JKSzVyPUCuOlM2QCEQvF2= MYrTRW5ITVJ?
SJSA-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPmO3k6UUN3ME2wMlY{PzJ3IN88US=> NFHYT4RUSU6JRWK=
HOP-62 NHLGVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIWwSlZKSzVyPUCuOlUxOzNizszN M1fjbXNCVkeHUh?=
KGN MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvzZ2tCUUN3ME2wMlY3OTZ6IN88US=> MoPRV2FPT0WU
D-336MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwNk[xOlkh|ryP NGD4dnVUSU6JRWK=
LS-411N NEP6dIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLrUHZQUUN3ME2wMlY4PDZ{IN88US=> NF7TNGxUSU6JRWK=
TE-1 NX7LSJZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkflTWM2OD1yLk[5NFc1KM7:TR?= NH\leVhUSU6JRWK=
LB996-RCC NELEN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q2SGlEPTB;MD62PVM5QSEQvF2= NGDuXZFUSU6JRWK=
TE-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwN{G0PVYh|ryP NIPCeGZUSU6JRWK=
NCI-SNU-16 M3zk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\CbWlEPTB;MD63NlY3PCEQvF2= MUnTRW5ITVJ?
ES8 M1rCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwN{S5O|Uh|ryP MV;TRW5ITVJ?
COLO-800 MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;XUYpKSzVyPUCuO|Y3QTVizszN M1XCN3NCVkeHUh?=
ES6 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW5TWM2OD1yLke3OVU6KM7:TR?= MmrCV2FPT0WU
L-363 MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\3ZWJKSzVyPUCuPFI{PzVizszN MYPTRW5ITVJ?
NMC-G1 NGG3TFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHIZZZKSzVyPUCuPFMzOzNizszN NFThcWxUSU6JRWK=
LU-134-A MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XjeWlEPTB;MD64N|kyOiEQvF2= NFzkeJpUSU6JRWK=
SF268 NG\ROGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwOESwOFIh|ryP MYLTRW5ITVJ?
KARPAS-45 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zyPWlEPTB;MD64OFI3OyEQvF2= NILCZ4tUSU6JRWK=
TGW NYjzZWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jh[2lEPTB;MD64OVg3OyEQvF2= MXLTRW5ITVJ?
CHP-126 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvUTWM2OD1yLki1PVU4KM7:TR?= NGW3fGFUSU6JRWK=
MOLT-16 NE\rWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwOEe1PFkh|ryP M4X3[3NCVkeHUh?=
LB771-HNC NEm4eoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGridW9KSzVyPUCuPFk4PTdizszN M1HlbHNCVkeHUh?=
NALM-6 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjvTZdKSzVyPUCuPVA4OzlizszN M2O0THNCVkeHUh?=
GCIY M3;SR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LRSGlEPTB;MD65OVUzPiEQvF2= M3GxNnNCVkeHUh?=
IST-MES1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwOUi4NlQh|ryP M{\vWHNCVkeHUh?=
LB2241-RCC MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v0TmlEPTB;MD65PFg1KM7:TR?= M1HDdXNCVkeHUh?=
BL-70 NIrSR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO4TWM2OD1yLkm5OVM2KM7:TR?= M3XNd3NCVkeHUh?=
NB17 Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG4Wm1KSzVyPUGuNFA3OzlizszN M2rBUXNCVkeHUh?=
LXF-289 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDhXlBKSzVyPUGuNFMxPzZizszN NIL1RpFUSU6JRWK=
TK10 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP5WmpKSzVyPUGuNFUxPjNizszN NFXBeYdUSU6JRWK=
K5 NWPTe|Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTHTWM2OD1zLkC2Nlc1KM7:TR?= MnO4V2FPT0WU
NCI-H716 M2rJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[5RWlEPTB;MT6wO|I2QSEQvF2= NXnUVmlCW0GQR1XS
HCE-T M1K3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3VPWxKUUN3ME2xMlA5QDF7IN88US=> MXvTRW5ITVJ?
GI-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwMEm3PVgh|ryP Ml\HV2FPT0WU
KARPAS-422 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\EO2lEPTB;MT6xNFAzOiEQvF2= MWTTRW5ITVJ?
TE-9 NGXUPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwMUGzNlgh|ryP NVLheFN1W0GQR1XS
SF126 MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\SblZKSzVyPUGuNVE2PjhizszN NVH6NnlyW0GQR1XS
BB30-HNC NI\sXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nlUWlEPTB;MT6xN|EyOiEQvF2= MYfTRW5ITVJ?
NCI-H1304 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvGfWlXUUN3ME2xMlE{OzN6IN88US=> MXPTRW5ITVJ?
HEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfXTWM2OD1zLkG0PFk2KM7:TR?= MnTaV2FPT0WU
HAL-01 NH\m[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwMUWyPFMh|ryP NYf0[mh2W0GQR1XS
SK-LMS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwMUW5O|Qh|ryP MmfzV2FPT0WU
SW954 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf2SIFKSzVyPUGuNVk2PjdizszN MlyzV2FPT0WU
D-283MED NGm0WpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHJS4lTUUN3ME2xMlIzOzd7IN88US=> MnPaV2FPT0WU
NCI-H1882 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jYdmlEPTB;MT6yN|g6KM7:TR?= M3ryT3NCVkeHUh?=
GI-ME-N MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT3W2hKSzVyPUGuNlUzODhizszN NXvOd41HW0GQR1XS
SK-PN-DW MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17tV2lEPTB;MT6yOlM1QCEQvF2= MorlV2FPT0WU
C2BBe1 NG\GS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrVfGdKSzVyPUGuNlkyOTdizszN NHrofGxUSU6JRWK=
A704 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSzTWM2OD1zLkOyOlg6KM7:TR?= MX;TRW5ITVJ?
KALS-1 NI\rRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFwM{SwPEDPxE1? MY\TRW5ITVJ?
ETK-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rybWlEPTB;MT6zOFQ5QSEQvF2= NV;pc21mW0GQR1XS
LB647-SCLC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGzTWM2OD1zLkO0PVg3KM7:TR?= MofJV2FPT0WU
OCUB-M Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqxTWM2OD1zLkO2NVQ{KM7:TR?= MXrTRW5ITVJ?
NCI-H720 NF7JSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HCOWlEPTB;MT6zOlM4QCEQvF2= NHu0R4dUSU6JRWK=
NB13 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHq[JlKSzVyPUGuN|czQTNizszN MUTTRW5ITVJ?
GR-ST MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i4eGlEPTB;MT6zPFc2PyEQvF2= M1fLS3NCVkeHUh?=
DU-4475 NHnSfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTnRlU5UUN3ME2xMlQ2QDV|IN88US=> MWPTRW5ITVJ?
HCC2157 NHnwZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDmTWM2OD1zLkS2OlU6KM7:TR?= NVfVSHQ{W0GQR1XS
RKO M37wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\nTWM2OD1zLkS5PVIzKM7:TR?= NU\WXnJiW0GQR1XS
LS-123 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwNUG1PVQh|ryP NUfCfHp[W0GQR1XS
NCI-H69 NX3k[XJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrhSVNKSzVyPUGuOVU5OTFizszN NFHqcllUSU6JRWK=
SW962 M2Xo[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G3b2lEPTB;MT61OlE{KM7:TR?= M4TuOnNCVkeHUh?=
PF-382 M4TKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwNU[5OkDPxE1? NWDFTpFWW0GQR1XS
A101D NEXxToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLlTWM2OD1zLkW3NVE{KM7:TR?= NWfoT5JkW0GQR1XS
NB10 M3vmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXvbWFiUUN3ME2xMlU4Ozl{IN88US=> MmXYV2FPT0WU
NB5 NIDLOJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HEZ2lEPTB;MT61PFQ4PiEQvF2= NVLBSVhMW0GQR1XS
HCE-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPBTWM2OD1zLk[wPFUh|ryP MUPTRW5ITVJ?
HT-144 NFvtSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j4emlEPTB;MT62N|E6KM7:TR?= NYXOSXYzW0GQR1XS
NCI-H524 M2HaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwNkSzNFch|ryP M37Zd3NCVkeHUh?=
NKM-1 M4XxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkexTWM2OD1zLk[4OlYh|ryP MlTaV2FPT0WU
KURAMOCHI NHPyR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwNkm1O|Mh|ryP M1nmNXNCVkeHUh?=
NCI-H187 MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwN{CwN|Yh|ryP NVXCSmFMW0GQR1XS
U-266 NGjteJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfSc4dKSzVyPUGuO|M5PDJizszN NVj5XHdKW0GQR1XS
BL-41 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwN{[yO|Ih|ryP MU\TRW5ITVJ?
SK-N-DZ NUHtfZBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHSTWM2OD1zLke4N|A6KM7:TR?= MnHSV2FPT0WU
Daudi M1LUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO5T3lKSzVyPUGuO|g6PjdizszN NUDVbY9FW0GQR1XS
CPC-N MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD5TWM2OD1zLki1NFk3KM7:TR?= MljOV2FPT0WU
EM-2 NYn1UopQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTLTWM2OD1zLki1NUDPxE1? MVjTRW5ITVJ?
HCC1187 NEHQPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\rdYdKSzVyPUGuPFYzPDFizszN M1viT3NCVkeHUh?=
LP-1 NWXSbmtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwOEexOFMh|ryP MkPiV2FPT0WU
CAS-1 NITtR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\oTWM2OD1zLkm4Nlk6KM7:TR?= MX7TRW5ITVJ?
NB7 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG5TWM2OD1{LkCwOVU2KM7:TR?= MWnTRW5ITVJ?
VA-ES-BJ NXT3[VlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7BbJA6UUN3ME2yMlAyPTF|IN88US=> NXK1UJpQW0GQR1XS
SNU-C2B NGXEUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;5V|UzUUN3ME2yMlA{OzVzIN88US=> NXXEVXduW0GQR1XS
LOXIMVI NHroO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f1bmlEPTB;Mj6wOlc5PiEQvF2= NGHHVmZUSU6JRWK=
NCI-H1581 M3P3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TrfmlEPTB;Mj6xNVU2QSEQvF2= MoTRV2FPT0WU
IST-SL2 NHzJSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPCTWM2OD1{LkGyOFQ2KM7:TR?= Ml7IV2FPT0WU
NOMO-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDJb3VKSzVyPUKuNVc3QDNizszN Mn3oV2FPT0WU
TE-6 NEfXbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJwMUmwOUDPxE1? MYLTRW5ITVJ?
NCI-H526 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\RZYdKSzVyPUKuNVkyPDFizszN MmPSV2FPT0WU
MSTO-211H MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwMkCwOFEh|ryP M3f6TnNCVkeHUh?=
LS-513 NHHQOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[wcWlEPTB;Mj6yNlI3QSEQvF2= MkL0V2FPT0WU
NCI-SNU-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwM{OyOVYh|ryP NEfJSW5USU6JRWK=
BB65-RCC Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTQcJQ2UUN3ME2yMlM4PDl|IN88US=> M1m1dnNCVkeHUh?=
GT3TKB MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvoTWM2OD1{LkO5PVczKM7:TR?= NFTpNmFUSU6JRWK=
OS-RC-2 NF7hWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTIOVBCUUN3ME2yMlQzOzRzIN88US=> NUW0bmNsW0GQR1XS
NCI-H2126 NVjuXZlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDWSW5KSzVyPUKuOFM3PzRizszN NF3O[opUSU6JRWK=
SK-UT-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3aSFFyUUN3ME2yMlQ4PDZ5IN88US=> MX3TRW5ITVJ?
DMS-114 NGribo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrjXppkUUN3ME2yMlYyPTJ2IN88US=> MWfTRW5ITVJ?
ONS-76 MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwNkO2OFEh|ryP MWLTRW5ITVJ?
8-MG-BA NFTFcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rxOmlEPTB;Mj62OVQyPCEQvF2= MWPTRW5ITVJ?
BOKU Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OwU2lEPTB;Mj63Nlc3PCEQvF2= Mm\1V2FPT0WU
LAMA-84 NFfkd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLzb|JKSzVyPUKuO|k6OTJizszN NHTGUXNUSU6JRWK=
ES1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwOEG4NFQh|ryP Mn\mV2FPT0WU
NCI-H1395 NF:wcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX4TWM2OD1{LkiyNFEzKM7:TR?= MYnTRW5ITVJ?
A388 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v6SmlEPTB;Mj65OlE4KM7:TR?= MXTTRW5ITVJ?
NCCIT MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CwcWlEPTB;Mz6wPFg3OiEQvF2= MVfTRW5ITVJ?
HD-MY-Z NIjOUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTNwMUOyNFMh|ryP MX7TRW5ITVJ?
NCI-H510A MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj4N4lKSzVyPUOuNVg6PDNizszN NWS1Z5A1W0GQR1XS
NCI-N87 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTaTWM2OD1|LkKwNFIh|ryP M{[4SHNCVkeHUh?=
SCLC-21H M1;tPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImzdolKSzVyPUOuNlY5PTlizszN NV\o[GY4W0GQR1XS
SH-4 NHz3O2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj6PVFKUUN3ME2zMlI5Pzl5IN88US=> M4S1PXNCVkeHUh?=
QIMR-WIL NXXLS3F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\ITWM2OD1|LkOyPFQ6KM7:TR?= NYS4VVd[W0GQR1XS
KM12 NF\uNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmyS2tiUUN3ME2zMlM{PTR2IN88US=> MUXTRW5ITVJ?
ST486 NV3sNGtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvCNpdOUUN3ME2zMlU{QDh|IN88US=> NX3VcJpbW0GQR1XS
HC-1 M{n1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PHWGlEPTB;Mz62NlAzQCEQvF2= M1mweXNCVkeHUh?=
BV-173 NFT1OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzBfnpKSzVyPUOuOlQxQDhizszN NUXj[XYzW0GQR1XS
EW-24 NIPpWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jMc2lEPTB;Mz62OlQ{PCEQvF2= NHe2TIJUSU6JRWK=
LU-65 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jKdmlEPTB;Mz62PFcyKM7:TR?= MlPNV2FPT0WU
ECC4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfoeZdKSzVyPUOuO|c2PiEQvF2= MoPpV2FPT0WU
ARH-77 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPpTWM2OD12LkGxNFY4KM7:TR?= MXrTRW5ITVJ?
BC-3 NW\DbmY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDFPVdKSzVyPUSuNVMxPjhizszN M1flXnNCVkeHUh?=
SNB75 M{XRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjtTWM2OD12LkK2NVkh|ryP NXuw[Y4xW0GQR1XS
MEG-01 NGjZOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fyZWlEPTB;ND6yO|QyQSEQvF2= NYe2d5QxW0GQR1XS
NCI-H1417 NHvufmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorzTWM2OD12LkK4OFQ{KM7:TR?= NVX1OlFPW0GQR1XS
MDA-MB-134-VI NG\aZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LVSWlEPTB;ND6zNFYxOSEQvF2= NXP2PGk6W0GQR1XS
Becker NF3KXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTRwNEezN|Yh|ryP M1[zTXNCVkeHUh?=
DMS-153 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTIZplKSzVyPUSuOlY1PzVizszN NHvpOFJUSU6JRWK=
TGBC1TKB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqwNoZKSzVyPUSuOlg2OTVizszN M1vsVnNCVkeHUh?=
EW-3 MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHsTWM2OD12Lke2NlQ5KM7:TR?= NVWzT2xvW0GQR1XS
KE-37 NWfIXI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRwOE[xPVYh|ryP M2nRbXNCVkeHUh?=
NCI-H23 NWOxcVVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\hTWM2OD12Lki3NlI4KM7:TR?= M3uy[XNCVkeHUh?=
MC116 M3WyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofyTWM2OD12Lkm0NVI3KM7:TR?= NG[5SIVUSU6JRWK=
NH-12 NVjrTIJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwOU[0N|kh|ryP MYLTRW5ITVJ?
CTB-1 MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LLc2lEPTB;ND65O|czOSEQvF2= M{HEdXNCVkeHUh?=
KM-H2 NI\uSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\2TWM2OD13LkC1N|I{KM7:TR?= MXXTRW5ITVJ?
MOLT-4 NYnX[no5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH0TWM2OD13LkGxPFMh|ryP M2LRbXNCVkeHUh?=
NCI-H2141 NHjhXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfNToRKSzVyPUWuNVQzPjhizszN M3XU[HNCVkeHUh?=
EB-3 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrhRphKSzVyPUWuNVc2ODRizszN MnnBV2FPT0WU
NCI-H1522 NEjOR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnQ[3VHUUN3ME21MlI3OzJ{IN88US=> NHT1WIRUSU6JRWK=
MRK-nu-1 NYr3bpptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nQeGlEPTB;NT60N|Y{OyEQvF2= MWPTRW5ITVJ?
no-11 M4SzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTVwNEewPFch|ryP MlTGV2FPT0WU
CESS MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fSe2lEPTB;NT61PFA{PCEQvF2= MV3TRW5ITVJ?
KMOE-2 M2O0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTVwNUi2OVkh|ryP NIjlephUSU6JRWK=
REH M4W4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTZwMkW2NVgh|ryP MnzZV2FPT0WU
KU812 NVv6[VltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HxW2lEPTB;Nj60Nlc6OSEQvF2= MnHVV2FPT0WU
SK-N-FI NIjFPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfyN3l7UUN3ME22MlYxPjd2IN88US=> MVjTRW5ITVJ?
MMAC-SF MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGyblE3UUN3ME23MlA3PDl{IN88US=> MoTQV2FPT0WU
RCC10RGB M1z1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly2TWM2OD15LkKyPVc4KM7:TR?= MXzTRW5ITVJ?
NCI-H322M NYTPXJFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTdwM{OzN|Uh|ryP M2DDbHNCVkeHUh?=
NB6 M2juO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXRNGtKSzVyPUeuOVQ5QTlizszN M{jBenNCVkeHUh?=
MN-60 NUTWOGlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTdwNkmyNVUh|ryP NEXhU3lUSU6JRWK=
NCI-H1092 NIHDS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPX[IdKSzVyPUiuNFE4OzRizszN NWrqRoVtW0GQR1XS
EKVX NGLWboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GyS2lEPTB;OD60O|A3PiEQvF2= MnK5V2FPT0WU
D-263MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL1TWM2OD16LkW1N|k3KM7:TR?= MYDTRW5ITVJ?
NCI-H209 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPH[FVKSzVyPUiuOlQxODZizszN MWLTRW5ITVJ?
IST-SL1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHOTWM2OD16Lki5PFkzKM7:TR?= MXzTRW5ITVJ?
ACN MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nJUGlEPTB;OT6xPVE2PyEQvF2= NIj2eJFUSU6JRWK=
MHH-PREB-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;NPYdKSzVyPUmuNlEzOTlizszN MnTVV2FPT0WU
EW-11 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfBTWM2OD17Lk[1N|k3KM7:TR?= MlTFV2FPT0WU
KASUMI-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTlwN{i3O{DPxE1? MnvUV2FPT0WU
KINGS-1 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL3dY06UUN3ME2xNE4zOzR5IN88US=> NUfyVYdoW0GQR1XS
EVSA-T M1;a[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fJVWlEPTB;MUCuN|E6OiEQvF2= MWrTRW5ITVJ?
DSH1 M1KzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFyLkO5O|Ih|ryP M1TqW3NCVkeHUh?=
COLO-824 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrWWWJKSzVyPUGwMlg3PjlizszN NFm1dppUSU6JRWK=
K052 MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqwTWM2OD1zMD65N|IzKM7:TR?= MVXTRW5ITVJ?
SK-MEL-2 NYHFdlE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknBTWM2OD1zMD65PVM6KM7:TR?= MYjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]

Protocol

Kinase Assay:[1]
+ Expand

In vitro Enzyme Assays.:

All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.
Cell Research:[1]
+ Expand
  • Cell lines: Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
  • Concentrations: 1 nM-10 μM
  • Incubation Time: 2–3 days
  • Method: Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
  • Formulation: Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
  • Dosages: 1, 3, and 10 mg/kg
  • Administration: Once daily by oral gavage for 3 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (4.88 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol, pH 4
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

Related ALK Products

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID